Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)
Others
Ratios

BioLineRx (BLRX) EBT: 2023-2025

Historic EBT for BioLineRx (BLRX) over the last 2 years, with Jun 2025 value amounting to -$2.0 million.

  • BioLineRx's EBT rose 45.04% to -$2.0 million in Q2 2025 from the same period last year, while for Jun 2025 it was -$7.7 million, marking a year-over-year increase of 80.04%. This contributed to the annual value of -$11.3 million for FY2024, which is 76.25% up from last year.
  • Per BioLineRx's latest filing, its EBT stood at -$2.0 million for Q2 2025, which was down 2.84% from -$2.0 million recorded in Q1 2025.
  • In the past 5 years, BioLineRx's EBT registered a high of $54,000 during Q4 2024, and its lowest value of -$19.5 million during Q4 2023.
  • In the last 3 years, BioLineRx's EBT had a median value of -$3.8 million in 2024 and averaged -$6.3 million.
  • Data for BioLineRx's EBT shows a peak YoY spiked of 100.28% (in 2024) over the last 5 years.
  • Over the past 3 years, BioLineRx's EBT (Quarterly) stood at -$19.5 million in 2023, then spiked by 100.28% to $54,000 in 2024, then surged by 45.04% to -$2.0 million in 2025.
  • Its EBT stands at -$2.0 million for Q2 2025, versus -$2.0 million for Q1 2025 and $54,000 for Q4 2024.